Active Ingredient(s): Tafamidis
FDA Approved: * May 3, 2019
Pharm Company: * FOLDRX PHARMS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Vyndamax Overview

Tafamidis, sold under the brand names Vyndaqel and Vyndamax,[3] is a medication used to delay disease progression in adults with certain forms of transthyretin amyloidosis (ATTR). It can be used to treat both hereditary forms (hATTR), familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP), as well as wild-type transthyretin amyloidosis (wtATTR, formerly called senile systemic amyloidosis). It works by stabilizing the quaternary structure of the protein...

Read more Vyndamax Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Tafamidis

Recent Vyndamax Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 20mg, 61mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Vyndamax: (1 result)

Sorted by National Drug Code
  • 0069-8730 Vyndamax 61 mg Oral Capsule, Liquid Filled by Pfizer Laboratories Div Pfizer Inc

Other drugs which contain Tafamidis or a similar ingredient: (2 results)